Studying risk factors to help detect lung cancer earlier
Builds prediction models to spot lung cancer early, using risk tools, devices and cell analysis.
Plain-language title generated from the registry record
Registry title: Understanding Lung Cancer Related Risk Factors and Their Impact
Key facts
- Where
- Barakaldo and Seville, SpainSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 to 80 for lung cancer screening and early diagnosis. People at high risk of lung cancer and people with lung nodules or lung cancer found in screening can take part in later phases.
- Age
- 40 to 80 years
- Sex
- All genders; at least 37% of participants must be women.
- Disease stage
- Phase 2 (screening): people at high risk of lung cancer. Phase 3 (diagnosis): people with indeterminate pulmonary nodules or lung cancer found in the screening phases.
Main reasons for not taking part
- Current or past lung cancer
- Any other cancer in the last 5 years, except non-melanoma skin cancer
- Other serious illness that would prevent a diagnostic study or surgery
- Pregnant women
- Unable to be followed for at least 2 years
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT06473870, who can take part
Where in Spain
- Hospital Universitario CrucesBarakaldo, SpainContact: Eunate Arana-Arri, PhDNo longer taking part
- Aljarafe-Sevilla Norte Health DistrictSeville, SpainContact: Luis G Luque Romero, MDNo longer taking part
- Hospital Universitario Virgen MacarenaSeville, SpainContact: David Vicente-Baz, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Biobizkaia Health Research Institute
- Trial code
- NCT06473870
- Record updated
- 25 June 2024
- Original description
LUCIA aims to develop prediction models for the early diagnosis of lung cancer based on the identification of risk factors and deeper cellular knowledge, by recording real-world data; with risk assessment tools, non-invasive devices and omics analysis. These models will enable new clinical pathways and diagnostic workflow to be implemented to ensure early diagnosis and confirmation, including classification of lung cancer subtype.Read full original descriptionShow less
Understanding Lung Cancer Related Risk Factors and Their Impact
LUCIA aims to develop prediction models for the early diagnosis of lung cancer based on the identification of risk factors and deeper cellular knowledge, by recording real-world data; with risk assessment tools, non-invasive devices and omics analysis. These models will enable new clinical pathways and diagnostic workflow to be implemented to ensure early diagnosis and confirmation, including classification of lung cancer subtype.
Inclusion: Subjects aged between 40 and 80 years; Both genders, of which at least 37% must be women to ensure representativeness; Willingness and ability to comply with scheduled visits, laboratory tests, and other trial procedures; Written informed consent obtained prior to performing any protocol-related procedures; High risk of developing Lung Cancer volunteers will be selected by Lung Cancer risk factors modelling; Patients diagnosed with indeterminate pulmonary nodules or Lung Cancer from the screening phases.
Exclusion: Current or prior history of lung cancer; History of neoplasia in the previous 5 years except non-melanoma skin cancer; Moderate-severe comorbidities that prevent completion of a diagnostic study in the event of findings suggestive of lung neoplasia (by means of the investigator's clinical judgment) or surgical intervention (< 6 months) if not previously confirmed by cytohistology; Vulnerable subjects: severe psychiatric comorbidity, adults under guardianship or deprived of liberty; Subjects under 40 years of age; Unable to be followed-up for at least 2-years or complete the study; Subjects that do not sign the informed consent; Pregnant women.